Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edesa Biotech, Inc.EDSA · Entity 7223 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edesa Biotech, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 49,417 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 19,000 · Balance 49,417 F1: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. |
| Common SharesSEC Table I · non-derivative | IndirectHeld by York-Cav Enterprises, Inc. | 522 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 522 F2: York-Cav Enterprises, Inc. is partially owned by the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.
F2: York-Cav Enterprises, Inc. is partially owned by the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 21:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-003800 · ownership.xml · nonDerivative · entry 1 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,417 F1 · shares: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. F1 · price: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. Read SEC document |
| May 29, 2025 Filed Jun 3, 2025 01:24 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 20,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003591 · ownership.xml · nonDerivative · entry 1 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,417 F1 · shares: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. F1 · price: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:02 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 10,416 | $1.92 | $19,998.72 |
DisclosureSEC source: 0001171843-25-000869 · ownership.xml · nonDerivative · entry 1 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,416 F1 · price: On February 12, 2025, the Reporting Person purchased in a private placement, 10,416 common shares, without par value, of the Issuer, for a purchase price of $1.92 per share. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 20:30 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantShare Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001654954-23-009527 · section16.xml · derivative · entry 1 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2023-07-20 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant. Read SEC document |
| July 20, 2023 Filed Jul 24, 2023 20:46 UTC Amendment | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantShare Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001654954-23-009599 · section16.xml · derivative · entry 1 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant. Read SEC document |
| February 28, 2022 Filed Mar 8, 2022 00:40 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001654954-22-002654 · section16.xml · derivative · entry 1 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Shares · 11,000 shares Expires 2032-02-28 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the Grant Date. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 20:53 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001654954-21-004626 · section16.xml · derivative · entry 1 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2031-04-22 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the Grant Date. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 15:04 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | OtherCommon Share Warrants (Right to Buy) · Derivative | 1,218 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001654954-20-011927 · section16.xml · derivative · entry 2 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common shares · 1,218 shares Expires 2020-11-08 F1 · ownership.nature: York-Cav Enterprises, Inc. is partially owned by the reporting party. Mr. Sistilli disclaims beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 15:04 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | OtherCommon shares | 1,218 | $4.00 | $4,872.00 |
DisclosureSEC source: 0001654954-20-011927 · section16.xml · nonDerivative · entry 1 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by York-Cav Enterprises, Inc. Disclosed balance after: 3,654 F1 · ownership.nature: York-Cav Enterprises, Inc. is partially owned by the reporting party. Mr. Sistilli disclaims beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 19:57 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.44 | $0.00 |
DisclosureSEC source: 0001654954-20-011152 · section16.xml · derivative · entry 1 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common shares · 20,000 shares Expires 2030-10-13 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 36 months beginning on the Grant Date. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 11,389 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001654954-20-001647 · section16.xml · derivative · entry 1 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,389 Underlying: Common Shares · 11,389 shares Expires 2030-02-12 F1 · derivative.exercise_date: 33% vested on 2/12/2020, with a prorata amount of the balance vesting monthly thereafter over the next 36 months until fully vested Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 19:13 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Share Warrants (Right to Buy) · Derivative | 1,218 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001654954-20-000269 · section16.xml · derivative · entry 3 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by York-Cav Enterprises, Inc. Disclosed balance after: 1,218 Underlying: Common Shares · 1,218 shares Expires 2020-11-08 F4 · security: Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020. F1 · price: The reported securities are included within 2,436 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. F2 · ownership.nature: York-Cav Enterprises, Inc. is partially owned by the reporting party.Mr. Sistilli disclaims beneficial ownership except to the extent of his precautionary interest therein. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 19:13 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Share Warrants (Right to Buy) · Derivative | 1,827 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001654954-20-000269 · section16.xml · derivative · entry 2 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by York-Cav Enterprises, Inc. Disclosed balance after: 1,827 Underlying: Common Shares · 1,827 shares Expires 2023-07-08 F3 · security: Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023. F1 · price: The reported securities are included within 2,436 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. F2 · ownership.nature: York-Cav Enterprises, Inc. is partially owned by the reporting party.Mr. Sistilli disclaims beneficial ownership except to the extent of his precautionary interest therein. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 19:13 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 2,436 | $4.11 | $10,011.96 |
DisclosureSEC source: 0001654954-20-000269 · section16.xml · nonDerivative · entry 1 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by York-Cav Enterprises, Inc. Disclosed balance after: 2,436 F1 · price: The reported securities are included within 2,436 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. F2 · ownership.nature: York-Cav Enterprises, Inc. is partially owned by the reporting party.Mr. Sistilli disclaims beneficial ownership except to the extent of his precautionary interest therein. Read SEC document |
| January 08, 2020 Filed Jan 13, 2020 13:30 UTC Amendment | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Share Warrants (Right to Buy) · Derivative | 1,218 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001654954-20-000336 · section16.xml · derivative · entry 3 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by York-Cav Enterprises, Inc. Disclosed balance after: 1,218 Underlying: Common Shares · 1,218 shares Expires 2020-11-08 F4 · security: Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020. F5 · kind: Amended to reflect acquisition from the issuer. F1 · price: The reported securities are included within 2,436 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. F2 · ownership.nature: York-Cav Enterprises, Inc. is partially owned by the reporting party.Mr. Sistilli disclaims beneficial ownership except to the extent of his precautionary interest therein. Read SEC document |
| January 08, 2020 Filed Jan 13, 2020 13:30 UTC Amendment | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Share Warrants (Right to Buy) · Derivative | 1,827 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001654954-20-000336 · section16.xml · derivative · entry 2 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by York-Cav Enterprises, Inc. Disclosed balance after: 1,827 Underlying: Common Shares · 1,827 shares Expires 2023-07-08 F3 · security: Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023. F5 · kind: Amended to reflect acquisition from the issuer. F1 · price: The reported securities are included within 2,436 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. F2 · ownership.nature: York-Cav Enterprises, Inc. is partially owned by the reporting party.Mr. Sistilli disclaims beneficial ownership except to the extent of his precautionary interest therein. Read SEC document |
| January 08, 2020 Filed Jan 13, 2020 13:30 UTC Amendment | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 2,436 | $4.11 | $10,011.96 |
DisclosureSEC source: 0001654954-20-000336 · section16.xml · nonDerivative · entry 1 Sistilli Carlo · CIK 0001777988 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by York-Cav Enterprises, Inc. Disclosed balance after: 2,436 F5 · kind: Amended to reflect acquisition from the issuer. F1 · price: The reported securities are included within 2,436 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. F2 · ownership.nature: York-Cav Enterprises, Inc. is partially owned by the reporting party.Mr. Sistilli disclaims beneficial ownership except to the extent of his precautionary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.